I-Mab Stock (IMAB) - Quote Nasdaq- MarketScreener (2024)

I-MAB

Add to a list

To use this feature you must be a member

Log inSign up

Equities

IMAB

US44975P1030

Pharmaceuticals
Market Closed - Nasdaq

Other stock markets

04:00:00 2024-09-27 pm EDT
5-day change 1st Jan Change
1.150 USD +3.60% I-Mab Stock (IMAB) - Quote Nasdaq- MarketScreener (2) +6.48% -39.47%
Sep. 23 I-Mab Announces Board and Committee Changes CI
Sep. 23 CI

Valuation: I-Mab

(USD)

Capitalization 93.65M P/E ratio 2024 *

-3.38x

P/E ratio 2025 * -4.11x
Enterprise value 93.65M EV / Sales 2024 *

-

EV / Sales 2025 * -
Free-Float

90.8%

Yield 2024 *

-

Yield 2025 * -

More valuation ratios * Estimated data

Chart: I-Mab

Dynamic Chart

Latest news: I-Mab

I-Mab Announces Board and Committee Changes Sep. 23 CI
Sep. 22 CI
I-Mab Cancer Drug Trial Shows 'Encouraging' Topline Data Sep. 16 MT
I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024 Sep. 16 CI
I-Mab, H1 2024 Earnings Call, Aug 28, 2024 Aug. 28
Earnings Flash (IMAB) I-MAB BIOPHARMA Posts Q2 Loss $-0.07 Per Share Aug. 28 MT
Tranche Update on I-Mab's Equity Buyback Plan announced on August 17, 2023. Aug. 28 CI
I-Mab Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 Aug. 28 CI
I-Mab's Equity Buyback announced on July 31, 2024 has expired with 3,804,453 shares, representing 4.6% for $5.2 million. Jul. 30 CI
I-Mab Names Wei Fu Chairman, Sean Xi-Yong Fu as Interim CEO Jul. 15 MT
I-Mab Announces Chief Executive Officer Changes Jul. 15 CI
I-Mab Announces Board and Committee Changes Jul. 15 CI
I-Mab Appoints Phillip Dennis as Chief Medical Officer Jun. 06 CI

More news

Last Transcript: I-Mab

I-Mab Stock (IMAB) - Quote Nasdaq- MarketScreener (3)

I-Mab, H1 2024 Earnings Call, Aug 28, 2024

Aug. 28

More transcripts

Analysts' recommendations: I-Mab

Piper Sandler Adjusts Price Target on I-Mab to $10 From $15, Maintains Overweight Rating Mar. 18 MT
Needham Cuts Price Target on I-Mab to $6 From $8, Maintains Buy Rating Mar. 15 MT
Needham Trims I-Mab Price Target to $23 From $24, Maintains Buy Rating 23-09-25 MT
HC Wainwright Adjusts Price Target on I-Mab to $18 From $25, Maintains Buy Rating 23-08-18 MT
Needham Lowers Price Target on I-Mab to $24 From $33, Maintains Buy Rating 23-04-03 MT

More recommendations

Press Releases: I-Mab

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024 Sep. 16 PR
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer Sep. 10 PR
I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference Aug. 26 PR
I-Mab to Release 1H 2024 Financial Results on August 28, 2024 Aug. 14 PR
I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP Aug. 08 AQ

More press releases

Quotes and Performance

1 day+3.60%
1 week+6.48%
Current month+1.77%
1 month-8.73%
3 months-31.95%
6 months-38.50%
Current year-39.47%

More quotes

Course Extremes

1 month

1.02

I-Mab Stock (IMAB) - Quote Nasdaq- MarketScreener (5)

1.32

Current year

0.99

I-Mab Stock (IMAB) - Quote Nasdaq- MarketScreener (6)

2.54

1 year

0.99

I-Mab Stock (IMAB) - Quote Nasdaq- MarketScreener (7)

2.54

3 years

0.99

I-Mab Stock (IMAB) - Quote Nasdaq- MarketScreener (8)

76.81

5 years

0.99

I-Mab Stock (IMAB) - Quote Nasdaq- MarketScreener (9)

85.40

10 years

0.99

I-Mab Stock (IMAB) - Quote Nasdaq- MarketScreener (10)

85.40

More quotes

Managers and Directors: I-Mab

Director TitleAgeSince

Jerry Wang CTO

Chief Tech/Sci/R&D Officer - -

Tyler Ehler IRC

Investor Relations Contact - 21-05-31

Yi Fei Zhu PRN

Corporate Officer/Principal 55 20-08-09
Manager TitleAgeSince

Wei Fu CHM

Chairman 42 18-05-31

Chun Kwok Au BRD

Director/Board Member 51 19-12-31

Chia Hung Yang BRD

Director/Board Member 61 19-12-31

More insiders

ETFs: I-Mab

Name Weight AuM 1st Jan change Investor Rating

FIRST TRUST CHINDIA ETF - USD

0.79% 96 M€ -.--% -

LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD

0.57% 4 M€ -27.92%

LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD

0.03% 0 M€ 0.00% -

LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD

0.02% 0 M€ 0.00% -

SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD

0.00% 4 M€ -4.41% -

More ETFs: I-Mab

Other Pharmaceuticals

Add to a list

Add to a list

0 selected

To use this feature you must be a member

Log inSign up

Change 5d. change 1-year change 3-years change Capi. ($)

I-MAB

+3.60%+6.48%-6.50%-98.36%93.65M

ELI LILLY AND COMPANY

-3.47%-4.74%+59.67%+287.72%790B

NOVO NORDISK A/S

-4.59%-6.29%+23.01%+152.14%529B

+0.01%-1.68%+2.73%-1.08%389B

ABBVIE INC.

+1.51%+0.68%+27.21%+80.83%344B

+0.53%-2.97%+9.38%+54.98%288B

ROCHE HOLDING AG

+0.59%+1.11%+8.02%-19.36%260B

ASTRAZENECA PLC

-0.56%-1.07%+4.82%+36.03%242B

NOVARTIS AG

+0.03%-1.11%+5.92%+27.75%235B

AMGEN INC.

+1.12%-4.36%+19.96%+51.41%173B
Average +0.20%-1.24%+15.42%+57.20% 325.08B
Weighted average by Cap. -0.45%-2.12%+24.78%+113.88%

See all sector performances

Financials

(USD)

2024 *2025 *
Net sales - -
Net income -35.16M -75.37M
Net Debt - -

More financial data * Estimated data

Company Profile

I-Mab Stock (IMAB) - Quote Nasdaq- MarketScreener (26)

I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.

Employees

34

Sector

Pharmaceuticals

Calendar

2025-03-25 - Q4 2024 Earnings Release (Projected)

More about the company

Quotes

Date Price Change Volume
24-09-27 1.150 $ +3.60% 418,135
24-09-26 1.110 $ +3.74% 456,003
24-09-25 1.070 $ -3.60% 1,749,564
24-09-24 1.110 $ +5.71% 588,699
24-09-23 1.050 $ -2.78% 216,572

Delayed Quote Nasdaq, September 27, 2024 at 04:00 pm EDT

More quotes

Income Statement and Estimates

I-Mab Stock (IMAB) - Quote Nasdaq- MarketScreener (27)

More financial data

Analysts' Consensus

Sell

I-Mab Stock (IMAB) - Quote Nasdaq- MarketScreener (28)

Buy

Mean consensus

BUY

Number of Analysts

4

Last Close Price

1.150USD

Average target price

6.750USD

Spread / Average Target

+486.96%

Consensus

Profit revisions

I-Mab Stock (IMAB) - Quote Nasdaq- MarketScreener (29)

Estimate revisions

Quarterly earnings, Rate of surprise

I-Mab Stock (IMAB) - Quote Nasdaq- MarketScreener (30)

Company calendar

  1. Stock Market
  2. Equities
  3. IMAB Stock
"); for (var element in ICConf) { if (document.getElementById("zpp"+element)) { document.getElementById("zpp"+element).innerHTML = ""; } } InvestingChannelQueue.push(function() { ic_page = InvestingChannel.UAT.Run("5c5a75c3-8896-4592-98f8-dc06e6fdcc56"); }); } $(document).ready(function() {gaEvent('adspv', 'InvestingChannel_v2', 'US');});googletag.cmd.push(function() { googletag.pubads().setTargeting('Edition', 'en_US');googletag.pubads().setTargeting('UserType', 'free');googletag.pubads().setTargeting('Content', 'equities');googletag.pubads().setTargeting('codezb', '95388118');googletag.enableServices();googletag.pubads().collapseEmptyDivs();try{googletag.pubads().getSlots().forEach(function(slot){if(slot.getSlotElementId().startsWith('zpp')){;}else{googletag.pubads().refresh([slot],{changeCorrelator: false});}})}catch(error){console.error(error)}});$(document).ready(function() { $( document).on('zbv_visible',function () {startAdsService();}); if (document[zbv_hidden]===false) { startAdsService(); } });
I-Mab Stock (IMAB) - Quote Nasdaq- MarketScreener (2024)
Top Articles
Latest Posts
Recommended Articles
Article information

Author: Nathanial Hackett

Last Updated:

Views: 6499

Rating: 4.1 / 5 (52 voted)

Reviews: 91% of readers found this page helpful

Author information

Name: Nathanial Hackett

Birthday: 1997-10-09

Address: Apt. 935 264 Abshire Canyon, South Nerissachester, NM 01800

Phone: +9752624861224

Job: Forward Technology Assistant

Hobby: Listening to music, Shopping, Vacation, Baton twirling, Flower arranging, Blacksmithing, Do it yourself

Introduction: My name is Nathanial Hackett, I am a lovely, curious, smiling, lively, thoughtful, courageous, lively person who loves writing and wants to share my knowledge and understanding with you.